Currently Up Early This Morning, ATNM Could Be On The Verge Of A Continued Vertical Move On Yesterday's News

Currently Up Early This Morning, ATNM Could Be On The Verge Of A Continued Vertical Move On Yesterday's News [ATNM Analyst Consensus Price Target Of $67.50]( November 5th FierceAnalyst Reader, After an early push to the $12.05 mark, ATNM is battling back towards $12.00 resistance this morning. If that level caves today, we could see a strong vertical push due to several potential driver indicators I highlighted in the report below. Plus, with [yesterday's major press]( release still making the rounds, ATNM will be one to watch closely the rest of the week as the company news could be a true game-changer. Barchart has also upgraded ATNM up to an "80% BUY" as of this morning. If you haven't read my initial report on ATNM below, do so now and get it on your radar. ----- The markets are open so let's dive in quickly. Recently, I brought this profile to your attention and watched as it ran approximately $1.00+ intraday after I alerted it last month. Now, with major news out yesterday, it's important to get this NYSE biopharma idea back on your radar: Actinium Pharmaceuticals, Inc. (ATNM) Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. And as I mentioned above, ATNM dropped some game-changing news yesterday that could provide a breakout spark for this profile to make a strong vertical move up the charts. Read now: 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML - 70% of patients achieving remission were MRD-negative with remissions and MRD negativity reported in all dose cohorts - Data to be presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission. [Read the full article here.]( ATNM And The Significant Unmet Medical Need Meeting an unmet medical need can be the Holy Grail for pharmaceutical companies. Look at Actinium Pharmaceuticals for example. At the moment, they are working towards achieving the treatment for Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Unfortunately, standard therapies for R/R acute myeloid leukemia just aren’t enough. Many patients either do not achieve complete response (CR) or relapse after CR, according to the National Center for Biotechnology Information. And although 70-80% of patients achieve CR, many patients are refractory to, or relapse, following treatment. Plus, there is a “lack of a uniform treatment strategy for this group, with the exception of allogeneic hematopoietic cell transplantation (HCT) as the only potentially curative treatment option for patients achieving a second complete remission.” ATNM May Hold The Key To This Unmet Need With yesterday's potentially game-changing results, it could be impressive. Not only for the company, but also for a patient population with a current five-year survival rate of 10%, according to [Blood](. Better, the remission rates of the Actinium Pharmaceuticals study are far more impressive when compared to other therapies that have been approved for treatment. As reported by Targeted Oncology, others aren’t even in the same ballpark. - 68% with gilteritinib (Xospata), - 64% with venetoclax (Venclexta) plus hypomethylating agents, - 40% with enasidenib (Idhifa), - 19% with venetoclax alone, and - 17% with azacytidine (Vidaza) alone ----- Potential Driver Indicators - Major Price Targets For ATNM These targets paint the picture of a potentially extremely undervalued profile: [Source - MarketBeat]( MarketBeat is also reporting that ATNM has a consensus price target of $67.50. From Wednesday's closing valuation of $11.29, that gives ATNM potential upside of approximately 497%. I'm not saying that ATNM is going to run over triple-digits today, but there are several analysts pointing to significant potential upside for this biopharma idea. On top of that, Actinium Pharmaceuticals has an analyst consensus of "[Strong Buy.]( More Driver Indicators : Red Hot Chart + Low Float + Bullish Technicals As you can see in the chart above, ATNM has proven to be a short-term wrecking back on multiple occasions over the past 6 months. From a September 4th low of $6.84 to an October high of $12.36, ATNM has been on the move. In a month and a half, ATNM climbed roughly 80%. How is this possible? For one, ATNM has a low float. According to Yahoo Finance, ATNM has a 12.34Mn shares in its float. When a profile has that few shares available, volatility can be in the cards. Volatility can provide the potential for sharp vertical moves in the short-term. It gets even better as ATNM is flashing strong, bullish technical indicators. [Barchart]( is reporting these triggered technicals as of close Wednesday: Short Term Indicators - 20 Day Moving Average - 20 - 50 Day MACD Oscillator - 20 - 200 Day MACD Oscillator Medium Term Indicators - 50 Day Moving Average - 50 - 150 Day MACD Oscillator - 50 - 200 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average - 100 - 200 Day MACD Oscillator Additionally ATNM is now a "64% BUY" overall based on technical indicators, up from Tuesday's "32% BUY." Even [Zacks Equity Research]( shared this recently, "Based on the most recent data, ATNM has returned 63.82% so far this year. Meanwhile, stocks in the Medical group have lost about 4.57% on average. This means that Actinium Pharmaceuticals is performing better than its sector in terms of year-to-date returns." ----- Another ATNM Potential Driver Indicator? Recent Key News Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225. This new research facility will function under the guidance of Dr. Dale Ludwig, Ph.D. the Company's Chief Scientific & Technology Officer, who has over twenty-five years of oncology discovery research and development experience, including supporting the development and launch of Erbitux®, CyramzaTM, Portrazza®, and LartruvoTM as well as the clinical advancement of at least 10 additional therapeutic antibodies and Antibody Drug Conjugates while at Eli Lilly and, previously, ImClone Systems Inc. The research facility will be managed and staffed by Ph.D. level scientists who will contribute their respective expertise in areas of drug discovery, radiation chemistry, and translational research to advance novel ARC programs and investigations into combination therapeutic strategies. "Our new research facility will allow us to significantly accelerate our preclinical and clinical development of novel ARC programs and investigate mechanistic ARC therapeutic combinations, which utilize our expertise in radioimmunobiology, our AWE Technology Platform capabilities, and know-how," said Dale Ludwig. "The establishment of an internal research facility was a priority for Actinium's long-term strategy, as we look to deliver on our pipeline development activities, as well as expand our portfolio of promising product candidates through partnerships and collaborations. Furthermore, in both preclinical and clinical studies, we have shown mechanistic synergies when our ARCs are combined with novel and approved therapeutic agents in treating cancer. The addition of this R&D facility will enable more rapid investigation of novel mechanistic drug combinations that can be effectively translated into clinical testing." Over the last eighteen months, Actinium has advanced its research and discovery activities in three key areas —the development of next generation ARCs, therapeutic combinations with ARCs, and improved targeted conditioning treatments for adoptive cell therapies such as CAR-T. As presented at the 2018 AACR Annual Meeting, cell death improved as much as thirty-fold and cell death occurred in treatment resistant cell lines when daratumumab, an anti-CD38 directed antibody approved for the treatment of multiple myeloma (MM), was labeled with Ac-225 using Actinium's AWE Technology Platform. The power and potency of Actinium's AWE Technology Platform is also demonstrated in an ongoing Actimab-A combination study with CLAG-M in difficult to treat R/R AML patients. Patients treated with a sub-therapeutic dose of Actimab-A combined with CLAG-M had improved response rates by over 60% versus CLAG-M treatment alone. In September, preclinical data supporting Iomab-ACT as a viable and effective method for achieving targeted lymphodepletion prior to an adoptive cell therapy such as CAR-T was published in the journal Oncotarget (. Leveraging the new laboratory facility, Actinium intends to further its research activities in these areas which will aid in developing next generation targeted conditioning agents and exploring therapeutic combinations with ARCs and of proven oncology and immunooncology agents. The Company intends to focus on generating novel ARCs, building on its existing intellectual property, evaluating assets for in-licensing to complement existing clinical pipeline, as well as securing collaborations and partnerships with other biopharmaceutical companies. By adding research and development capabilities to its clinical development and clinical supply chain capabilities, Actinium will be positioned to enable the rapid translation of radioimmunotherapies into the clinic. The Company's AWE platform intellectual property covers various methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. Actinium's AWE technology patent portfolio includes 29 patent families comprised of over 130 issued or pending global patent applications, of which 10 are issued and 31 pending in the United States. Sandesh Seth, Chairman and Chief Executive Officer of Actinium, said, "The opening of our R&D facility is an important milestone that will support both internal and collaborative efforts at advancing the field of ARCs. Our growing and highly talented R&D team is focused on harnessing the power of our AWE Technology Platform to enhance our clinical pipeline and drive current and additional collaborations. Having these capabilities in house will allow us to more efficiently execute on our multi-disciplinary research efforts and continue to innovate and extend our leadership position in the growing field of ARCs." ----- Recap: Top 5 Potential Driver Indicators For ATNM 1. ATNM's Big Breaking News From Wednesday Regarding "100% Remission Rate Reported." 2. Huge price targets and "Strong Buy" recommendations 3. Red hot chart and bullish technicals in the short, medium, and long terms 4. ATNM's low float under 13Mn shares 5. ATNM's recent news about a new research facility. ----- Coverage is officially initiated on ATNM. If there are any more updates today, I'll get them out to you quickly. Sincerely, Fierce Analyst | Jaks Swift Editorial Writer [Source 1]( [Source 2]( [Source 3]( [Source 4]( [Source 5]( I am not a licensed financial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. An owner of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierce investor . com (“FI”), an interest in the limited liability company that owns and operates stock street wire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, Stock Wire News, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between Fierce Investor (FI) and StockNewsWire, LLC, FI has been hired for a period beginning on 1/10/20 and ending on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (ATNM). A owner of StockNewsWire, LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/28/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 3/5/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between Fierce Investor (FI) and StockNewsWire, LLC, FI has been hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between Fierce Investor (FI) and StockWireNews LLC, FI has been hired for a period beginning on 11/5/20 and ending on 11/6/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We were paid five thousand USD via ACH. We own zero shares of (ATNM). To date, we have been compensated a total of fifteen thousand USD via ACH to disseminate information about (ATNM).    An owner of StockWireNews LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockWireNews LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 11/5/20 and ending on 11/6/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid thirty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). To date, we have been compensated a total of one hundred and two thousand five hundred USD via bank wire transfer to disseminate information about (ATNM).  Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [About our service provider]( Sent by jaks@fierceanalyst.net